HLA-DRB1 Protein (Myc-DYKDDDDK Tag)

Produktnummer ABIN2722844

Produktdetails

Target: HLA-DRB1 (Major Histocompatibility Complex, Class II, DR beta 1 (HLA-DRB1))

Protein-Typ: Recombinant

Spezies: Human

Quelle: HEK-293 Cells

Aufreinigungstag / Konjugat: Dieses HLA-DRB1 Protein ist gelabelt mit Myc-DYKDDDDK Tag.

Applikation: Antibody Production (AbP), Standard (STD)

Produktmerkmale:

• Recombinant human HLA-DRB1 protein expressed in HEK293 cells.
• Produced with end-sequenced ORF clone

Reinheit: > 80 % as determined by SDS-PAGE and Coomassie blue staining

Anwendungsinformationen

Applikationshinweise: Recombinant human proteins can be used for:
Native antigens for optimized antibody production
Positive controls in ELISA and other antibody assays

Kommentare:

The tag is located at the C-terminal.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 50 μg/mL

Buffer: 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10 % glycerol.

Lagerung: -80 °C

Informationen zur Lagerung: Store at -80°C. Thaw on ice, aliquot to individual single-use tubes, and then re-freeze immediately. Only 2-3 freeze thaw cycles are recommended.

Antigendetails

Target: HLA-DRB1 (Major Histocompatibility Complex, Class II, DR beta 1 (HLA-DRB1))

Andere Bezeichnung: Hla-Drb1 (HLA-DRB1 Produkte)

Synonyme: MGC108235 Protein, DRB1 Protein, DRw10 Protein, HLA-DR1B Protein, HLA-DRB Protein, SS1 Protein, major histocompatibility complex, class II, DR beta 1 Protein, hla-drb1 Protein, HLA-DRB1 Protein

Hintergrund: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-ce [UniProtKB/Swiss-Prot Function]

Molekulargewicht: 27 kDa

NCBI Accession: NP_002115

Pathways: T-Zell Rezeptor Signalweg, Positive Regulation of Peptide Hormone Secretion, Production of Molecular Mediator of Immune Response, CXCR4-mediated Signaling Events, Cancer Immune Checkpoints